1
|
Locatelli F, Pozzoni P, Tentori F and del
Vecchio L: Epidemiology of cardiovascular risk in patients with
chronic kidney disease. Nephrol Dial Transplant. 18:2–9. 2003.
View Article : Google Scholar : PubMed/NCBI
|
2
|
Hou FF, Ma ZG, Mei CL, et al: Epidemiology
of cardiovascular risk in Chinese chronic kidney disease patients.
Zhonghua Yi Xue Za Zhi. 85:753–759. 2005.(In Chinese).
|
3
|
Mitch WE, Du J, Bailey JL and Price SR:
Mechanisms causing muscle proteolysis in uremia: the influence of
insulin and cytokines. Miner Electrolyte Metab. 25:216–219. 1999.
View Article : Google Scholar : PubMed/NCBI
|
4
|
Price SR, Du JD, Bailey JL and Mitch WE:
Molecular mechanisms regulating protein turnover in muscle. Am J
Kidney Dis. 37(Suppl 2): 112–114. 2001. View Article : Google Scholar : PubMed/NCBI
|
5
|
Mitch WE: Robert H Herman Memorial Award
in Clinical Nutrition Lecture, 1997. Mechanisms causing loss of
lean body mass in kidney disease. Am J Clin Nutr. 67:359–366.
1998.PubMed/NCBI
|
6
|
Fukai T: Targeting proteasome worsens
atherosclerosis. Circ Res. 101:859–861. 2007. View Article : Google Scholar : PubMed/NCBI
|
7
|
Herrmann J, Soares SM, Lerman LO and
Lerman A: Potential role of the ubiquitin-proteasome system in
atherosclerosis: aspects of a protein quality disease. J Am Coll
Cardiol. 51:2003–2010. 2008. View Article : Google Scholar : PubMed/NCBI
|
8
|
Feng B, Zhang Y, Mu J, et al: Preventive
effect of a proteasome inhibitor on the formation of accelerated
atherosclerosis in rabbits with uremia. J Cardiovasc Pharmacol.
55:129–138. 2010. View Article : Google Scholar : PubMed/NCBI
|
9
|
Tao R, Lu L, Zhang R, Hu J, Ni J and Shen
W: Triptolide inhibits rat vascular smooth muscle cell
proliferation and cell cycle progression via attenuation of ERK1/2
and Rb phosphorylation. Exp Mol Pathol. 90:137–142. 2011.
View Article : Google Scholar : PubMed/NCBI
|
10
|
Little PJ, Ivey ME and Osman N:
Endothelin-1 actions on vascular smooth muscle cell functions as a
target for the prevention of atherosclerosis. Curr Vasc Pharmacol.
6:195–203. 2008. View Article : Google Scholar : PubMed/NCBI
|
11
|
Chung SW, Park JW, Lee SA, Eo SK and Kim
K: Thrombin promotes proinflammatory phenotype in human vascular
smooth muscle cell. Biochem Biophys Res Commun. 396:748–754. 2010.
View Article : Google Scholar : PubMed/NCBI
|
12
|
Newby AC: Matrix metalloproteinases
regulate migration, proliferation and death of vascular smooth
muscle cells by degrading matrix and non-matrix substrates.
Cardiovasc Res. 69:614–624. 2006. View Article : Google Scholar
|
13
|
Murata T and Shimotohno K: Ubiquitination
and proteasome-dependent degradation of human eukaryotic
translation initiation factor 4E. J Biol Chem. 281:20788–20800.
2006. View Article : Google Scholar : PubMed/NCBI
|
14
|
Murray AW: Recycling the cell cycle:
cyclins revisited. Cell. 116:221–234. 2004. View Article : Google Scholar : PubMed/NCBI
|
15
|
Ciechanover A and Iwai K: The ubiquitin
proteolytic system: from an idea to the patient bed. Proc Am Thorac
Soc. 3:21–31. 2006. View Article : Google Scholar : PubMed/NCBI
|
16
|
Gomes AV, Young GW, Wang Y, et al:
Contrasting proteome biology and functional heterogeneity of the 20
S proteasome complexes in mammalian tissues. Mol Cell Proteomics.
8:302–315. 2009. View Article : Google Scholar : PubMed/NCBI
|
17
|
Drews O, Wildgruber R and Zong C:
Mammalian proteasome subpopulations with distinct molecular
compositions and proteolytic activities. Mol Cell Proteomics.
6:2021–2031. 2007. View Article : Google Scholar : PubMed/NCBI
|
18
|
Groll M, Ditzel L, Löwe J, et al:
Structure of the 20S proteasome from yeast at 2.4 A resolution.
Nature. 386:463–471. 1997. View
Article : Google Scholar : PubMed/NCBI
|
19
|
Carbó C, Arderiu G, Escolar G, et al:
Differential expression of proteins from cultured endothelial cells
exposed to uremic versus normal serum. Am J Kidney Dis. 51:603–612.
2008.PubMed/NCBI
|